Bausch Health Companies (TSE:BHC) Upgraded at Barclays

Barclays upgraded shares of Bausch Health Companies (TSE:BHC) to a hold rating in a report published on Monday morning,Zacks.com reports.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at C$9.43 on Monday. The stock’s fifty day simple moving average is C$9.04 and its 200 day simple moving average is C$8.93. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. The company has a market capitalization of C$3.49 billion, a PE ratio of 9.72, a PEG ratio of 0.21 and a beta of 0.69. Bausch Health Companies has a 12 month low of C$5.91 and a 12 month high of C$11.97.

Bausch Health Companies (TSE:BHC) last posted its earnings results on Wednesday, October 29th. The company reported C$0.48 earnings per share (EPS) for the quarter. The business had revenue of C$2.68 billion during the quarter. Bausch Health Companies had a positive return on equity of 15.87% and a negative net margin of 1.88%. On average, research analysts predict that Bausch Health Companies will post 5.5472637 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.